View Older Stories View More Recent Stories

Apr 23, 2021 10:23AM "The New England Journal of Medicine" Publishes Results from Two Bimekizumab Phase 3 Studies in Moderate to Severe Plaque Psoriasis
Apr 23, 2021 10:22AM UCB to Present 12 Abstracts on Bimekizumab at AAD VMX 2021
Feb 25, 2021 07:00AM UCB Full Year Report 2020: UCB - sustaining growth, now and into the future
Feb 23, 2021 07:00AM UCB and Microsoft Expand Collaboration to Accelerate Drug Discovery and Development
Jan 13, 2021 07:00AM UCB Announces Launch of Nile AI, Inc., a Digital Health Company Set to Transform the Course of Epilepsy
Dec 4, 2020 07:00AM UCB Demonstrates Commitment to Science and Discovery Across Its Epilepsy Portfolio at the American Epilepsy Society's Virtual Event AES2020
Dec 1, 2020 08:00AM Specifica Delivers Antibody Platform to UCB to Speed up Development of New Therapeutics
Nov 30, 2020 04:45PM World's Leading Life Science Companies Now Enrolling COMMUNITY, A Global, Platform Trial For Hospitalized Patients With COVID-19
Nov 17, 2020 07:00AM UCB's VIMPAT® (lacosamide) CV now approved by FDA for primary generalized tonic-clonic seizures and expanded pediatric use for people living with epilepsy
Nov 12, 2020 07:00AM UCB strengthens its gene therapy activities with additional pipeline programs, capabilities and platforms
Nov 5, 2020 06:00PM UCB Showcases Key Rheumatology Data at American College of Rheumatology Convergence 2020
Oct 31, 2020 02:05AM Bimekizumab Phase 3 Data Shows Superior Skin Clearance Over Humira® in Moderate-to-Severe Psoriasis Patients
Oct 7, 2020 06:00AM UCB and Aetion Announce Agreement to Enhance Real-World Evidence Generation to Advance Value-Based Contracts
Sep 22, 2020 07:00AM UCB Achieves Important Regulatory Milestone for Bimekizumab
Aug 31, 2020 07:00AM Phase 3 data on VIMPAT® (lacosamide) CV in primary generalized tonic-clonic seizures published in Journal of Neurology, Neurosurgery & Psychiatry
Jul 29, 2020 07:00AM UCB enters into collaboration with Roche to develop antibody treatment for people living with Alzheimer's Disease
Jul 27, 2020 07:00AM UCB Half Year Report 2020
Jul 7, 2020 01:00PM UCB and Ferring Pharmaceuticals Announce Co-Promotion of CIMZIA® (certolizumab pegol) for the Treatment of Adults with Moderate to Severe Crohn's Disease
Jun 12, 2020 03:15PM First Presentations of Bimekizumab Phase 3 Data Demonstrate Superior Skin Clearance Over Placebo and Stelara® at Week 16 in Adults with Moderate-to-Severe Plaque Psoriasis
Jun 5, 2020 07:00AM UCB Acquires Engage Therapeutics: Staccato® Alprazolam - A potential Solution for Acute On-demand Seizure Management for People Living With Epilepsy
Apr 10, 2020 09:00AM UCB's General Meeting of Shareholders
Apr 2, 2020 09:30AM UCB Completes the Acquisition of Ra Pharmaceuticals - to Deliver Differentiated Therapies to Patients
Dec 12, 2019 06:20AM Amgen (AMGN), UCB Announce EC Approves EVENITY for Treatment of Severe Osteoporosis in Postmenopausal Women at High Risk of Fracture
Dec 12, 2019 01:00AM European Commission Approves EVENITY® (romosozumab) For The Treatment Of Severe Osteoporosis In Postmenopausal Women At High Risk Of Fracture
Dec 9, 2019 07:45PM UCB Presents Final Results from Phase II Study of Rozanolixizumab in Primary Immune Thrombocytopenia (ITP) at 2019 ASH Annual Meeting
Dec 6, 2019 07:00AM Bimekizumab Phase 3 Psoriasis Study Demonstrates Superiority Versus Humira®
Dec 5, 2019 07:00AM UCB Presents New Data Demonstrating Commitment to Epilepsy at 2019 American Epilepsy Society Meeting
Nov 25, 2019 07:00AM UCB Announces availability of NAYZILAM® (midazolam) Nasal Spray CIV, the first and only nasal rescue treatment for seizure clusters in the U.S.
Nov 15, 2019 07:00AM Bimekizumab Positive Results Confirmed in Second Phase 3 Psoriasis Study
Nov 8, 2019 09:10AM UCB Presents New Data From Rheumatology Portfolio Addressing Unmet Needs in Axial Spondyloarthritis, Psoriatic Arthritis and Lupus at 2019 ACR/ARP
Oct 18, 2019 01:00AM EVENITY® (Romosozumab) Receives Positive CHMP Opinion For The Treatment Of Severe Osteoporosis In Postmenopausal Women At High Risk Of Fracture
Oct 17, 2019 07:00AM Bimekizumab Phase 3 Psoriasis Study Meets All Endpoints, Achieving Significantly Greater Efficacy Versus Placebo and Ustekinumab
Oct 10, 2019 07:00AM UCB Agrees to Acquire Ra Pharmaceuticals: Joining Forces to Improve Treatment Options for People Living With Myasthenia Gravis and Other Rare Diseases
Jul 25, 2019 07:00AM UCB Half Year Report 2019: UCB's Strong Performance Enables Continued Investment Into Future Growth Drivers
Jun 28, 2019 01:00AM Amgen and UCB Provide Regulatory Update on Status of EVENITY™ (romosozumab) in the EU
Jun 14, 2019 07:00AM UCB's Key Pipeline Molecule Bimekizumab Demonstrated Improved Outcomes for Ankylosing Spondylitis Patients
May 28, 2019 08:01AM UCB Initiates Phase 1b US-Based Multicenter Clinical Trial in Parkinson’s Disease Patients with UCB0599, a Compound Arising from the Neuropore-UCB Collaboration
May 20, 2019 07:00AM UCB announces NAYZILAM® (midazolam) nasal spray now approved by FDA to treat intermittent, stereotypic episodes of frequent seizure activity in people living with epilepsy in the U.S.
Apr 9, 2019 03:59PM Amgen (AMGN) Confirms FDA Approves EVENITY For Treatment Of Osteoporosis in Postmenopausal Women
Apr 9, 2019 03:57PM FDA Approves EVENITY™ (romosozumab-aqqg) For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture
Mar 28, 2019 06:30PM CIMZIA® (certolizumab pegol) is Now the First and Only U.S. FDA-Approved Treatment for Non-Radiographic Axial Spondyloarthritis
Mar 2, 2019 07:00AM Bimekizumab Demonstrated Long-Term Maintenance of Complete or Almost Complete Skin Disease Resolution for Psoriasis Patients in BE ABLE 2 Extension Study
Mar 1, 2019 07:15AM New Data Affirms Strength of UCB Immuno-Dermatology Portfolio
Mar 1, 2019 07:08AM New Data Affirms Strength of UCB Immuno-Dermatology Portfolio
Jan 16, 2019 05:44PM Amgen (AMGN), UCB Confirm Positive Vote From FDA Panel in Favor of Approval for EVENITY (romosozumab)
Jan 16, 2019 05:41PM Amgen And UCB Receive Positive Vote From FDA Advisory Committee In Favor Of Approval For EVENITY™ (romosozumab)
Jan 8, 2019 04:01PM Amgen (AMGN), ECB Announce EVENITY Received Approval In Japan For Treatment of Osteoporosis
Jan 8, 2019 04:00PM EVENITY™ (romosozumab) Receives Approval In Japan For The Treatment Of Osteoporosis In Patients At High Risk Of Fracture
Nov 30, 2018 04:00PM Amgen (AMGN), UCB Announce FDA Advisory Committee Meeting To Review EVENITY
Nov 30, 2018 04:00PM Amgen And UCB Announce FDA Advisory Committee Meeting To Review EVENITY™ (romosozumab) For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture
View More Recent Stories View Older Stories